PMID- 37906445
OWN - NLM
STAT- MEDLINE
DCOM- 20231219
LR  - 20240124
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 16
IP  - 12
DP  - 2023 Jul-Dec
TI  - The delicate balance of graft versus leukemia and graft versus host disease after 
      allogeneic hematopoietic stem cell transplantation.
PG  - 943-962
LID - 10.1080/17474086.2023.2273847 [doi]
AB  - INTRODUCTION: The curative basis of allogeneic hematopoietic stem cell 
      transplantation (HSCT) relies in part upon the graft versus leukemia (GvL) 
      effect, whereby donor immune cells recognize and eliminate recipient malignant 
      cells. However, alloreactivity of donor cells against recipient tissues may also 
      be deleterious. Chronic graft versus host disease (cGvHD) is an immunologic 
      phenomenon wherein alloreactive donor T cells aberrantly react against host 
      tissues, leading to damaging inflammatory symptoms. AREAS COVERED: Here, we 
      discuss biological insights into GvL and cGvHD and strategies to balance the 
      prevention of GvHD with maintenance of GvL in modern HSCT. EXPERT 
      OPINION/COMMENTARY: Relapse remains the leading cause of mortality after HSCT 
      with rates as high as 40% for some diseases. GvHD is a major cause of morbidity 
      after HSCT, occurring in up to half of patients and responsible for 15-20% of 
      deaths after HSCT. Intriguingly, the development of chronic GvHD may be linked to 
      lower relapse rates after HSCT, suggesting that GvL and GvHD may be complementary 
      sides of the immunologic foundation of HSCT. The ability to fine tune the balance 
      of GvL and GvHD will lead to improvements in survival, relapse rates, and quality 
      of life for patients undergoing HSCT.
FAU - Maurer, Katie
AU  - Maurer K
AUID- ORCID: 0000-0002-4160-181X
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical 
      School, Boston, MA, USA.
FAU - Soiffer, Robert J
AU  - Soiffer RJ
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical 
      School, Boston, MA, USA.
LA  - eng
GR  - P01 CA229092/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20231218
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
SB  - IM
MH  - Humans
MH  - Quality of Life
MH  - *Graft vs Host Disease/etiology/prevention & control
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - *Leukemia/therapy
MH  - Chronic Disease
MH  - Recurrence
OTO - NOTNLM
OT  - Chronic graft versus host disease
OT  - GvHD
OT  - GvL
OT  - HSCT
OT  - relapse
EDAT- 2023/10/31 18:43
MHDA- 2023/12/19 06:41
CRDT- 2023/10/31 12:23
PHST- 2023/12/19 06:41 [medline]
PHST- 2023/10/31 18:43 [pubmed]
PHST- 2023/10/31 12:23 [entrez]
AID - 10.1080/17474086.2023.2273847 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2023 Jul-Dec;16(12):943-962. doi: 
      10.1080/17474086.2023.2273847. Epub 2023 Dec 18.